Pneumonia
Gregory Perry
cardiology
Flecainide After PCI: 35 Years After CAST, Is It Time to Reconsider Class Ic Antiarrhythmics in Coronary Artery Disease?
Infectious Diseases
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
Infectious Diseases
Surviving Sepsis Campaign 2026: A Comprehensive Pharmacotherapy Review
The SSC 2026 Guidelines represent the most comprehensive sepsis update since 2021 — with major changes to antibiotic selection, vasopressor targets, fluid resuscitation, and a new strong recommendation for prolonged beta-lactam infusion.
pharmacology
Time of Death: Diphenhydramine — A Pharmacist's Case for Abandoning a Relic of 20th-Century Medicine
Diphenhydramine has occupied American medicine for over 70 years. A pharmacologist with 30 years of clinical experience makes the case that it's time to stop prescribing out of habit and start prescribing based on evidence.
Infectious Diseases
Rethinking C. diff Treatment: Is Fidaxomicin Worth the Money?
The TAPER-V trial forces us to ask a question we should have been asking all along — would fidaxomicin have demonstrated superiority if the original trials had used longer follow-up?
cardiology
2026 ACC/AHA Dyslipidemia Guideline: A Comprehensive Pharmacotherapy Review
The 2026 ACC/AHA Dyslipidemia Guideline represents the most significant overhaul of lipid management since 2018 — introducing specific cholesterol targets and an expanded pharmacotherapeutic armamentarium.